Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Safety & Efficacy of Genakumab in Patients With Frequent Flares

The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).

A multicenter, randomized, double-blind, double-dummy, active-controlled study was to demonstrate the efficacy of Genakumab versus compound betamethasone injection in adult patients with frequent gouty arthritis attacks in whom non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine are contraindicated, are not tolerated, or do not provide an adequate response.

Inclusion Criteria:

• Male or female, 18 years ≤ age ≤75 years
• BMI≤40kg/m2
• Meeting ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout.
• Start of acute gout flare within 4 days prior to enrolled
• History of ≥ 2 gout flares within the 12 months prior to study start
• Evidence of contraindication (absolute or relative), or intolerance, or lack of efficacy for either NSAIDs and/or colchicines
• Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)

Exclusion Criteria:

-